Drug Search Results
Using advanced filters...
Advanced Search [+]

Flupirtine

Alternative Names: flupirtine, katadolon
Clinical Status: Active
Latest Update: 2025-06-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GLUN Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Brazil | Germany | India | Lithuania | Portugal | Russia

Approved Indications: None

Known Adverse Events: None

Company: Sichuan Baili Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flupirtine

Countries in Clinic: China

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Acute Pain|Spasm

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20131588

P1

Active, not recruiting

Spasm|Acute Pain

None

2025-04-29

Treatments

CTR20131585

P1

Active, not recruiting

Acute Pain|Spasm

None

2025-04-29

CTR20131587

P1

Active, not recruiting

Acute Pain|Spasm

None

2025-04-29

Treatments